Patents by Inventor Stephen Andrew Hitchcock
Stephen Andrew Hitchcock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7595339Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.Type: GrantFiled: August 17, 2007Date of Patent: September 29, 2009Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, Jr., Daryl Lynn Smith
-
Publication number: 20080287504Abstract: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.Type: ApplicationFiled: August 17, 2007Publication date: November 20, 2008Inventors: Jennifer Rebecca Allen, Albert Kudzovi Amegadzie, Kevin Matthew Gardinier, George Stuart Gregory, Stephen Andrew Hitchcock, Paul J. Hoogestraat, Winton Dennis Jones, JR., Daryl Lynn Smith
-
Patent number: 7378447Abstract: The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptorType: GrantFiled: March 12, 2004Date of Patent: May 27, 2008Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Stephen Andrew Hitchcock, William Wilson Turner, Bin Liu
-
Patent number: 7326731Abstract: The present invention relates to compounds of Formula I: Formula I which are agonists of the M-1 muscarinic receptor.Type: GrantFiled: September 9, 2002Date of Patent: February 5, 2008Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Stephen Andrew Hitchcock, James Andrew Jamison, Bin Liu, William Wilson Turner, Jr.
-
Patent number: 7265246Abstract: The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptorType: GrantFiled: June 23, 2004Date of Patent: September 4, 2007Assignee: Eli Lilly and CompanyInventors: Jennifer Rebecca Allen, Stephen Andrew Hitchcock, Bin Liu, William Wilson Turner
-
Patent number: 6939946Abstract: A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.Type: GrantFiled: September 30, 2003Date of Patent: September 6, 2005Assignee: Eli Lilly and CompanyInventors: Peter Stanley Borromeo, Jeffrey Daniel Cohen, George Stuart Gregory, Stacy Kay Henle, Stephen Andrew Hitchcock, Louis Nickolaus Jungheim, Daniel Ray Mayhugh, Timothy Alan Shepherd, William Wilson Turner, Jr.
-
Publication number: 20040242584Abstract: The present invention relates to compounds of Formula 1: Formula 1 which are agonists of the M-1 muscarinic receptor.Type: ApplicationFiled: March 3, 2004Publication date: December 2, 2004Inventors: Jennifer Rebecca Allen, Stephen Andrew Hitchcock, James Andrew Jamison, Bin Liu, William Wilson Turner
-
Patent number: 6653281Abstract: A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal omithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.Type: GrantFiled: May 24, 2001Date of Patent: November 25, 2003Assignee: Eli Lilly and CompanyInventors: Peter Stanley Borromeo, Jeffrey Daniel Cohen, George Stuart Gregory, Stacy Kay Henle, Stephen Andrew Hitchcock, Louis Nickolaus Jungheim, Daniel Ray Mayhugh, Timothy Alan Shepherd, William Wilson Turner, Jr.
-
Patent number: 6069238Abstract: An improved and a new synthetic route for the reparation of spirocyclic C-glycoside compounds having the following general structure are described. ##STR1## Novel derivatives of spirocyclic C-glycoside compounds are also disclosed which may be used as intermediates in the synthesis and evaluation of potential pharmaceutically active materials.Type: GrantFiled: June 28, 1999Date of Patent: May 30, 2000Assignee: Eli Lilly and CompanyInventors: Stephen Andrew Hitchcock, Chafiq Hamdouchi, Concepcion Sanchez-Martinez, Almudena Rubio Esteban